(Q33329493)

English

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (English)

1 reference

Europe PubMed Central

25 July 2017

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Roberto Labianca

object named as

R Labianca

4

0 references

Stefano Cascinu

object named as

S Cascinu

1

0 references

author name string

R R Silva

2

1 reference

Europe PubMed Central

25 July 2017

S Barni

3

1 reference

Europe PubMed Central

25 July 2017

L Frontini

5

1 reference

Europe PubMed Central

25 July 2017

E Piazza

6

1 reference

Europe PubMed Central

25 July 2017

G Pancera

7

1 reference

Europe PubMed Central

25 July 2017

P Giordani

8

1 reference

Europe PubMed Central

25 July 2017

L Giuliodori

9

1 reference

Europe PubMed Central

25 July 2017

M A Pessi

10

1 reference

Europe PubMed Central

25 July 2017

V Fusco

11

1 reference

Europe PubMed Central

25 July 2017

G Luporini

12

1 reference

Europe PubMed Central

25 July 2017

R Cellerino

13

1 reference

Europe PubMed Central

25 July 2017

G Catalano

14

1 reference

Europe PubMed Central

25 July 2017

language of work or name

0 references

publication date

1 July 1999

1 reference

Europe PubMed Central

25 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

25 July 2017

80

1 reference

Europe PubMed Central

25 July 2017

10

1 reference

Europe PubMed Central

25 July 2017

1595-1598

1 reference

Europe PubMed Central

25 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690568

0 references

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Chemotherapy for pancreatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Chemotherapy of adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

No standard treatment is available for advanced pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

21 June 2018

Cancer statistics, 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363090

31 October 2018

Chemotherapy for advanced pancreatic cancer - some light at the end of the tunnel?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should further studies of chemotherapy be carried out in pancreatic cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/10408405

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6690568

1 reference

Europe PubMed Central

25 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33329493&oldid=1953457124"